Get started
Precipio, Inc.Precipio, Inc.Precipio, Inc.

Precipio, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

PRPO trade ideas

$PRPO Precipio Inc Target PTs 11 --> 6.20 --> 14.80 and higherNASDAQ:PRPO Precipio Inc Target PTs 11 --> 6.20 --> 14.80 and higher Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.
NASDAQ:PRPOLong
by BADQOMOCAWGOWLD
$PRPO entry PT 1.86-1.98 Target PTs 4-4.50-8 and higherPrecipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
NASDAQ:PRPOLong
by BADQOMOCAWGOWLD
intraday creamWhile I'm a big proponent of free speech I don't like the word 'scalping' to describe intraday trading. Who the f came up with that f ing term? -conjures up some dark & evil shit in history. We have some real quality Wall St. d bags to thank for that. Anyway, this trade in PRPO today; some really nice clockwork in & out trades, she's pivoting well off the oscillators. folks you need PREMIUM to really get some good vantage of the 30s & 15s where some fast money can be made. Paid for my sub to premium just trading this beast move today. Cheers 🤙🏽
NASDAQ:PRPOLong
by QUANDRANTS
2
Launches Covid-19 Antibody Test in its CLIA laboratoryPrecipio Launches Covid-19 Antibody Test in its CLIA laboratory Completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory. Launched the test commercially to its pathology customer base (phase 1) Upon obtaining further approval for expanded use by FDA, phase 2 will broaden our distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices. Precipio is currently able to process 1,000 tests per day, increasing testing capacity to 10,000 tests per day by the end of Q3-20 as demand grows. Reimbursement is approximately $45 per test. finance.yahoo.com
NASDAQ:PRPO
by AlenCiken
Commercial Launch of COVID-19 Antibody TestPrecipio Announces Commercial Launch of COVID-19 Antibody Test PRPO entered into an agreement with ADS Biotec, a US company based in Omaha, Nebraska, to distribute its FDA-authorized COVID-19 serology antibody tests that recently received EUA (Emergency Use Authorization). Distribution of the product will take place in the US as well as in other markets worldwide. Precipio will begin rolling out these antibody tests initially as a CLIA test run in its laboratory (expected launch August); then further roll out (pending further FDA authorization) to physician offices as a POC (point-of-care) test; and finally, through distribution via various retail channels for at-home, DTC (direct-to-consumer) use. A recent Harvard University study indicates the need from 5 to 20 Million tests per day in the US. Current laboratory testing capacity in the US is estimated at only several hundred thousand per day. We believe that the only way to deliver testing at the scale required to achieve proper testing capacity would be through at-home use. finance.yahoo.com
NASDAQ:PRPO
by AlenCiken
$PRPO can rise in the next daysContextual immersion trading strategy idea. Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,51; stop-loss — $1,34. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:PRPOLong
by KozakHlib
2